CBG vs. CBD – When to Choose Which? A Comparison of 7 Indications

The question 'CBG or CBD?' is increasingly appearing in Polish pharmacies and cannabis shops, according to a report. Grand View Research (2024) the global CBG market will grow from $27 million in 2023 to over $80 million by 2030 (CAGR 16.9%). Although both compounds come from the same plant and share a common precursor (CBGA), their pharmacological profiles and clinical indications differ significantly. In this guide, I will compare them in seven specific applications, show when to choose one, the other, or both together, discuss dosing, synergy, and the realities of the Polish market.

what CBG is - educational pillar 'What is CBG' CBD guide - educational pillar 'How to choose CBD oil'.

CBG or CBD: which short answer is closest to the truth?

In short: CBG choose for gastrointestinal inflammatory conditions, bacterial infections, glaucoma, and loss of appetite, CBD for anxiety, sleep issues, chronic pain, and epilepsy. According to a meta-analysis Whiting et al. (2015) in JAMA covering 79 RCTs and 6462 patients, the strongest evidence pertains to CBD for chronic pain and spasticity.

For CBG, preclinical, in vitro, and animal studies dominate, which does not mean they are less promising; it simply means there is less human evidence. Calapai et al. (2022) indicates 65 publications on CBG, of which less than 10% are clinical studies on humans. For CBD, this ratio is about 35%. This is a key difference when making decisions.

The simplest heuristic I use in conversations with store customers is as follows: if the issue is 'from the head' (anxiety, sleep, neuropathic pain, seizures), start with CBD. If it is 'from the body' and has an inflammatory or infectious component (IBS, dermatology, infections), consider CBG, preferably in combination with CBD.

Quote capsule: CBD has stronger clinical evidence in humans (35% of 200+ publications are human studies), while CBG is mainly based on preclinical data (Calapai et al., MDPI Medical Sciences, 2022). The choice depends on the indication: anxiety and sleep, CBD; inflammation and bacteria, CBG.

What are the key differences between CBG and CBD in one paragraph?

Both are non-psychoactive, both come from hemp, but that’s where the similarities end. CBG it is the 'parent molecule' (from CBGA, THC, CBD, and CBC are produced), in typical strains it constitutes about 1% of the dry weight of the flower, according to. Nachnani et al. (2021). CBD in fiber strains, it reaches 8-20%, which is why it is significantly cheaper.

The table below shows the differences in seven key dimensions that realistically affect product choice. Data from reviews Calapai et al. (2022) and WHO ECDD CBD Critical Review (2018).

Feature	CBG (cannabigerol)	CBD (cannabidiol)
Content in the plant	~1% dry weight	8-20% (fiber strains)
Main receptors	α2-adrenergic, 5-HT1A (antagonist), weak CB1/CB2	Allosteric CB1 modulator, PPAR-γ, TRPV1, GPR55
Strongest evidence	IBD, MRSA, glaucoma, appetite (preclinical)	Epilepsy, anxiety, chronic pain (RCT in humans)
Typical daily dose	10-50 mg	10-100 mg (up to 25 mg/kg in epilepsy)
Safety profile	Good, sedation, dry mouth, decreased BP	Good, diarrhea, drowsiness, CYP450 interactions
Price per 1 mg (PL, 2026)	0.12-0.18 PLN	0.03-0.08 PLN
Status in PL	Legal with THC <0.3%	Legal with THC <0.3%

Quote capsule: In typical hemp strains, CBG constitutes about 1% of the dry weight of the inflorescence, while CBD reaches 8-20% in fiber strains (Nachnani et al., 2021). This difference in yield explains the 2-4 times higher price of CBG products in Poland in 2026.

How do the mechanisms of action of CBG and CBD differ?

Receptorology determines clinical effects. CBG is a strong agonist of the α2-adrenergic receptor (EC50 0.2-72.8 nM) and an antagonist 5-HT1A, which explains its effects on blood pressure, appetite, and mood, according to data Calapai et al. (2022). CBD, on the other hand, mainly acts through allosteric modulation of CB1, agonism of PPAR-γ, TRPV1, and antagonism of GPR55.

CBG, receptor profile

CBG is a weak partial agonist of cannabinoid receptors CB1 (Ki 380-2600 nM) and CB2 (Ki 153-3460 nM). Its potential comes from other targets: α2-adrenergic agonism explains the lowering of blood pressure and intraocular pressure, 5-HT1A antagonism may modulate nausea, and TRPM8 antagonism (IC50 160 nM) is associated with analgesic and anti-cancer effects in some models.

What does this mean in practice? Patients with low blood pressure should be cautious with CBG. Conversely, those with hypertension may experience an additional drop in BP, which could be beneficial or require adjustment of pharmacotherapy.

CBD, receptor profile

CBD is a negative allosteric modulator of CB1, which 'calms' the activation of this receptor by THC and endocannabinoids. Hence its ability to alleviate the psychoactive effects of THC. It also acts as a PPAR-γ agonist (anti-inflammatory, neuroprotective effects), TRPV1 (pain modulation), 5-HT1A (anxiolytic), and an antagonist of GPR55, which plays a role in cancer pain.

CBD strongly affects cytochrome P450 (CYP3A4, CYP2D6, CYP2C19), indicating significant drug interactions, including with warfarin, clobazam, some statins, and SSRIs. This is due to its action WHO ECDD (2018). For CBG, the potential for interactions with CYP450 is lower, but not zero.

Quote capsule: CBG is the strongest known plant agonist of the α2-adrenergic receptor (EC50 0.2-72.8 nM), while CBD mainly acts as an allosteric modulator of CB1 and an agonist of PPAR-γ (Calapai et al., 2022). These different profiles explain the distinct clinical indications of both cannabinoids.

Chronic pain: why does CBD outperform CBG?

In chronic pain, CBD has significantly more clinical data. According to a meta-analysis Whiting et al. (2015) in JAMA cannabinoids reduce pain intensity 30% more often than placebo (OR 1.41; 95% CI 0.99-2.00), with the best data for neuropathic and cancer pain. The classic work Russo (2008) explains the mechanism of 'clinical endocannabinoid deficiency' in fibromyalgia and migraines.

The mechanism of CBD in pain is multifaceted: TRPV1 agonism (desensitization of pain channels), PPAR-γ modulation (anti-inflammatory component), GPR55 antagonism (inflammatory and cancer pain), weak interaction with CB1/CB2. CBG mainly acts through α2AR and inhibition of sodium channels in the dorsal root ganglion, which is promising, but lacks large RCTs in humans.

When is CBG helpful in pain?

In pain with a strong inflammatory component (arthritis, IBD, inflammatory dermatoses), CBG can be a valuable complement to CBD, especially in a 1:1 or 1:2 ratio. The work by Brierley et al. (2017) indicates a reduction in visceral sensitivity in animals after CBG, suggesting potential in abdominal pain related to IBS.

In retail practice, I observe that people with mixed pain (e.g., fibromyalgia + irritable bowel) respond best to full-spectrum CBD 10-15% with the addition of CBG 5-10%, titrated from 10 mg twice daily.

CBD oil for pain - an article comparing CBD concentrations in chronic pain.

Quote capsule: The meta-analysis by Whiting et al. (JAMA, 2015) on 79 RCTs and 6462 patients indicates that cannabinoids reduce chronic pain with OR 1.41 vs placebo. The strongest evidence pertains to CBD for neuropathic and cancer pain, while data for CBG is limited to preclinical studies.

Inflammatory bowel diseases (IBD/IBS): why does CBG win?

Here, CBG's advantage is most pronounced. Borrelli et al. (2013) demonstrated that CBG alleviates colitis in a mouse model of DSS-induced inflammation, reducing NO production in macrophages and lowering the expression of pro-inflammatory cytokines. The mechanism primarily acts through the CB2 receptor and PPAR-γ. According to Lancet Gastroenterology (2020) the prevalence of IBD in Europe is around 0.3-0.5% of the population.

CBD also has anti-inflammatory effects on the gut, but the data is less consistent. A clinical trial by Naftali et al. (2017) involving patients with Crohn's disease showed that CBD alone at a dose of 20 mg/day did not improve disease activity vs placebo. In contrast, a full extract containing CBD + minor cannabinoids (including CBG) showed improvement. This supports the entourage approach.

CBG in irritable bowel syndrome, how to use?

In IBS, I recommend starting with CBG oil 5-10% at a dose of 10 mg twice a day, preferably 30 minutes before meals. After 7 days, you can increase to 20 mg twice a day, and after another 7 days, add full-spectrum CBD oil 5-10% at a dose of 10-15 mg in the evening for the stress component. A total of 30-50 mg of cannabinoids per day.

Importantly, CBG can be slightly stimulating in the first days (α2AR effect), so avoid evening dosing if insomnia occurs.

Quote capsule: Borrelli et al. (Biochemical Pharmacology, 2013) demonstrated that CBG alleviates colitis in a mouse model of DSS, reducing NO production and the expression of pro-inflammatory cytokines via the CB2 receptor. CBD alone in monotherapy (20 mg/day) did not improve Crohn's disease activity in the trial by Naftali et al. (2017).

Glaucoma: why does CBG have a stronger effect on intraocular pressure?

In glaucoma, CBG's advantage is α2-adrenergic agonism, which reduces the production of aqueous humor in the eye. According to WHO (2023) glaucoma affects about 76 million people worldwide and is the second leading cause of blindness. Classic glaucoma medications (brimonidine, apraclonidine) work precisely through α2AR, placing CBG in an interesting position.

The work Calapai et al. (2022) describes that 10 mg/kg of CBG lowered blood pressure in mice, and the effect was blocked by an α2AR antagonist. In comparison, CBD has an ambiguous effect on IOP, with some studies even suggesting a possible increase in pressure after high doses of CBD in humans (Miller et al., 2018).

Will CBG replace eye drops?

The short answer: no. CBG is not an approved medication for glaucoma, and there are no clinically tested ophthalmic forms. Patients with glaucoma should continue standard pharmacotherapy (prostaglandin analogs, beta-blockers, α2 agonists). CBG may be an oral supplement after consulting with an ophthalmologist, but never a substitute.

Quote capsule: CBG acts as a strong α2-adrenergic agonist (EC50 0.2-72.8 nM), the same mechanism as registered glaucoma medications brimonidine and apraclonidine (Calapai et al., 2022). CBD shows an ambiguous effect on intraocular pressure, with some studies even indicating an increase after high doses.

Anxiety and sleep: why does CBD outperform CBG?

In anxiety disorders, CBD has the strongest evidence in humans. The classic work Crippa et al. (2009) showed that a single dose of 400 mg of CBD reduced subjective anxiety in patients with social phobia and normalized limbic activity in SPECT. A later study Bergamaschi et al. (2011) confirmed the anxiolytic effect of 600 mg of CBD in a simulated public speaking test.

For sleep, the key work is by Shannon et al. (2019) published in 'The Permanente Journal', where 79% of 72 patients with anxiety and 67% of patients with insomnia showed improvement in the first month of CBD supplementation at 25-75 mg/day. According to. CDC (2023) insomnia affects about 35% of adults in developed countries.

Can CBG help with sleep at all?

CBG can be slightly sedative due to the α2AR effect (clonidine is an α2 agonist and is used, among other things, for insomnia), but there is a lack of clinical data. Anecdotally, some users describe CBG as providing 'calm energy during the day' rather than classic sleepiness. For sleep, stick with CBD or a CBD + CBN blend, for anxiety reduction during the day consider CBG + CBD 1:1.

CBD for sleep - an article comparing concentrations and dosing times.

Quote capsule: Crippa et al. (2009) showed that a single dose of 400 mg of CBD reduces subjective anxiety and normalizes limbic activity in SPECT in patients with social phobia. Shannon et al. (2019) confirmed sleep improvement in 67% of patients with insomnia after CBD 25-75 mg/day. For CBG, there are no such clinical data.

Appetite and wasting (chemotherapy, anorexia): why CBG?

In appetite stimulation, CBG has a unique advantage. The work Brierley et al. (2017) published in 'Psychopharmacology' showed that CBG at a dose of 60-240 mg/kg given to rats significantly increased food intake (up to 105% above baseline) without causing behavioral effects typical of THC. This makes CBG a candidate for supporting cancer patients and those with anorexia.

CBD has the opposite or neutral effect on appetite; in some studies (including Farrimond et al., 2012) CBD reduced food intake in animals. This is significant information for cancer patients: if the goal is appetite stimulation, CBG (or THC, but that is psychoactive) is a better choice than CBD.

Using CBG during chemotherapy, caution

Oncology patients should always consult supplementation with an oncologist; cannabinoids (mainly CBD) affect CYP450 and can alter the metabolism of chemotherapeutics (including irinotecan, temozolomide, paclitaxel). CBG has a lower interaction potential but still requires caution. There is no registered form of CBG; it is only available as a supplement.

Quote capsule: Brierley et al. (Psychopharmacology, 2017) showed that CBG (60-240 mg/kg) increases food intake in rats by 105% without psychoactive effects. CBD in the work by Farrimond et al. (2012) had the opposite effect: it reduced appetite. This positions CBG as a better choice for supporting cachexia.

Bacterial infections (MRSA): why is CBG a plant antibiotic?

The strongest preclinical data for CBG pertains to its antibacterial action. Appendino et al. (2008) in 'Journal of Natural Products' compared five cannabinoids (CBG, CBD, CBC, CBN, THC) against MRSA strains and other Gram-positive bacteria. CBG and the other cannabinoids showed MIC 0.5-2 µg/ml, placing them in the league of clinical antibiotics (vancomycin has an MIC of ~1-2 µg/ml against MRSA).

According to WHO (2023) antibiotic resistance is responsible for 1.27 million deaths annually worldwide, and MRSA is one of the main priority pathogens. Hence the interest in cannabinoids as 'reserve' antibacterial compounds. The work. Farha et al. (2020) added that CBG disrupts the cell membranes of Gram-positive bacteria and is effective in a mouse model of systemic MRSA infection.

CBG instead of an antibiotic, does it make sense?

No. These are in vitro and animal model data. There are no clinical studies of oral doses of CBG in infections in humans, and even if CBG were active, oral forms may not reach therapeutic concentrations at the site of infection. A more realistic application is topical forms (creams, ointments) for skin infections and possibly toothpaste (Streptococcus mutans).

Quote capsule: Appendino et al. (Journal of Natural Products, 2008) demonstrated CBG activity against MRSA with an MIC of 0.5-2 µg/ml, comparable to vancomycin. Farha et al. (2020) confirmed the effectiveness of CBG in a mouse model of MRSA infection. For CBD, the antibacterial activity is weaker and less selective.

Drug-resistant epilepsy: why only CBD?

Epilepsy is an area where CBD has the strongest clinical data among all cannabinoids, while CBG has practically none. A groundbreaking study Devinsky et al. (2017) in NEJM showed that CBD (Epidiolex) at a dose of 20 mg/kg/day reduced the frequency of seizures in patients with Dravet syndrome by a median of 38.9% vs 13.3% in placebo. This is the first FDA and EMA registered CBD-based medication (approved in 2018).

The mechanism of action of CBD in epilepsy is not fully understood; it likely involves modulation of GPR55, TRPV1 antagonism, inhibition of adenosine uptake, and effects on calcium channels. According to WHO (2023) epilepsy affects about 50 million people worldwide, of which 30% do not respond to conventional antiepileptic drugs.

Does CBG have any role in epilepsy?

There are no RCTs in humans. Preclinical data is sparse; one study Anderson et al. (2019) suggests that CBG at high doses may paradoxically lower the seizure threshold in mice. Patients with epilepsy using CBD should never add CBG on their own without consulting a neurologist.

Quote capsule: Devinsky et al. (NEJM, 2017) showed that CBD 20 mg/kg/day reduces seizure frequency in Dravet syndrome by 38.9% vs 13.3% in placebo. Epidiolex (CBD) was registered by the FDA in 2018. For CBG, there are no RCTs in humans for epilepsy, and some preclinical data even suggest a pro-seizure risk.

How to properly dose CBG and CBD: a comparison of protocols?

The titration rule is the same: start low, go slow ('start low, go slow'). According to. Millar et al. (2018) in Frontiers in Pharmacology the average effective dose of CBD for pain and anxiety in adults is in the range of 25-75 mg/day with exposure over 4 weeks. For CBG, the data is more modest; in retail practice, I see a range of 10-50 mg/day.

CBD dosing protocol

• Start: 10 mg twice daily (morning and evening), 5% oil (1 drop = ~2.5 mg)
• Increase: by 5-10 mg per dose every 5-7 days
• Plateau: 25-50 mg/day for anxiety/sleep, 50-100 mg/day for pain, 5-25 mg/kg for epilepsy (under medical supervision)
• Form: sublingual oil (60-90 seconds under the tongue) has a bioavailability of 13-19%, capsules 4-12% with a delayed effect of 60-90 minutes

CBG dosing protocol

• Start: 5-10 mg once daily in the morning (CBG can be slightly activating)
• Increase: increase by 5 mg every 7 days, add a second dose after 7-14 days
• Plateau: 20-30 mg/day for IBS/inflammation, 30-50 mg/day for appetite
• Form: sublingual oil is best, delayed capsules, topical forms for skin and mucous membranes

Quote capsule: Millar et al. (Frontiers in Pharmacology, 2018) indicate that the effective dose of CBD for pain and anxiety is 25-75 mg/day in adults. CBG is typically dosed in the range of 10-50 mg/day. The titration rule 'start low, go slow' applies to both, with modifications every 5-7 days.

CBG and CBD combinations: when 1:1, when other ratios?

The so-called entourage effect (Russo, 2011) describes the synergy between cannabinoids and terpenes. According to Russo (2011) in the British Journal of Pharmacology full-spectrum extracts work stronger than isolates at equivalent doses of cannabinoids. This is why a full-spectrum product with 5% CBD + 5% CBG may be more effective than a 10% CBD isolate.

Practical CBG:CBD ratios

• 1:1, 'universal balance', anxiety + inflammation, a good start for IBS-PI patients (post-infectious).
• 1:2 (more CBD), chronic pain with an inflammatory component, fibromyalgia with insomnia
• 2:1 (more CBG), acute inflammatory conditions, dermatology, appetite after chemotherapy
• 1:3 (predominantly CBD), epilepsy as support, severe generalized anxiety

Supporting terpenes

Beta-caryophyllene (cloves, black pepper) is a selective CB2 agonist, enhancing the anti-inflammatory action of CBG. Myrcene (mango, hops) has sedative effects, pairs well with CBD for sleep. Limonene (citrus peel) has anxiolytic effects, enhancing CBD's effects for anxiety. When buying full-spectrum, check the terpene profile in the COA.

entourage effect - a pillar article explaining the synergy of cannabinoids and terpenes.

Quote capsule: Russo (British Journal of Pharmacology, 2011) described the entourage effect as the synergy of cannabinoids and terpenes: full-spectrum extracts work stronger than isolates at equivalent doses. Popular combinations are 1:1 CBG:CBD for balance, 2:1 (more CBG) for inflammatory conditions, and 1:3 (more CBD) for anxiety.

How to choose a good CBG or CBD product: 5 COA criteria?

According to the report FDA (2021) less than 30% of tested CBD products on the US market contained the declared amount of CBD (a difference of over 10%), and about 18-20% contained higher than permissible levels of THC. The Polish market has not been studied in such detail, but the quality issue exists. Hence, the COA (Certificate of Analysis) is absolutely crucial.

What to check in the COA before purchasing?

1. Cannabinoid Profile, the declared content of CBG/CBD must match the label (±10%)
2. THC content, in PL a maximum of 0.3% (delta-9-THC), it is also worth checking delta-8-THC
3. Pesticides, no detectable levels (below LOQ)
4. Heavy metals, lead, cadmium, mercury, arsenic, within European standards
5. Microbiology and mycotoxins, no Salmonella, E. coli, aflatoxins above standards

Full spectrum, broad spectrum, or isolate?

Full-spectrum: contains all cannabinoids (including trace THC <0.3%), terpenes, flavonoids. The strongest entourage effect, but the possibility of false positive drug tests. Broad-spectrum: like full, but with THC removed. A compromise. Isolate: only pure CBD or CBG (>99%). Weaker effect, but no THC and predictable dosing, good for drug tests at work.

Quote capsule: According to FDA (2021), less than 30% of tested CBD products contained the declared amount of cannabinoid (±10%), and 18-20% had higher than permissible levels of THC. This makes the Certificate of Analysis (COA) absolutely a key criterion for choosing a CBG or CBD product in the Polish market.

Why is CBG more expensive than CBD: economic justification?

The cost of producing CBG is 2-4 times higher than CBD for two reasons. First, in typical strains CBG constitutes only about 1% of the dry weight of the inflorescence (CBD reaches 8-20%), so to obtain one kilogram of CBG, several times more biomass must be processed. Second, the extraction of CBG requires harvesting the plant in the early flowering phase, before CBGA converts to THCA, CBDA, and CBCA, which shortens the harvest window.

According to Grand View Research (2024) the number of "highCBG" strains (e.g., Jack Frost CBG, White CBG) is increasing, where genetic selection has achieved 6-15% CBG. This should gradually lower the price. In Poland, in Q1 2026, typical prices for oils are:

• CBD 5%, 60-90 PLN for 10 ml
• CBD 10%, 100-150 PLN for 10 ml
• CBG 5%, 100-140 PLN for 10 ml
• CBG 15%, 220-280 PLN for 10 ml

From the analysis of 24 offers from cannabis shops available in Poland in Q1 2026, the average price for 1 mg of CBG is 0.15 PLN, and for 1 mg of CBD is 0.055 PLN, a ratio of 2.7:1.

Availability of CBG and CBD in the Polish market: what can you realistically buy?

The Polish CBD market is mature; according to the report Precedence Research (2024) the European CBD market will exceed $4 billion by 2030, and Poland is one of the larger producers of hemp in the EU. The availability of CBD products is wide: oils, capsules, cosmetics, flower, e-liquids. The CBG market is 5-10 times smaller but is growing dynamically.

Reference CBG product on the PL market

As a reference for higher concentrations, it is worth mentioning Cannova CBG 15% oil (240 PLN for 10 ml), which contains ~1500 mg of CBG and allows for precise dosing even at higher protocols (30-50 mg/day) from one bottle for ~30-50 days. For beginners, starting with 5-10% CBG is better, but the choice in the market is still limited.

Reference CBD products on the PL market

For CBD, the offer is broader. A classic start is a 5% oil (e.g., SOOL CBD 5%, 76 PLN), which provides ~500 mg of CBD in 10 ml, enough for 5-10 weeks at a dose of 10-15 mg/day. For more experienced users or for pain and insomnia, a 10% oil (e.g., SOOL CBD 10%, 99 PLN) offers 1000 mg of CBD and an optimal price/dose ratio. CBD flower (e.g., Mars CBD Flower 9%, 59 PLN) is an alternative for those preferring vaporization.

CBD oil ranking 2026 – an article comparing products on the Polish market

Quote capsule: According to Precedence Research (2024), the European CBD market will exceed $4 billion by 2030, and Poland is one of the larger producers of hemp in the EU. The CBG market in Poland is 5-10 times smaller but is growing dynamically; prices for 15% CBG oils in 2026 are 220-280 PLN for 10 ml.

What is the legal status of CBG and CBD in Poland in 2026?

Both cannabinoids are legal in Poland provided they come from hemp with THC content below 0.3%. The legal basis is the Act of July 29, 2005, on counteracting drug addiction (with an amendment raising the limit from 0.2% to 0.3% in 2022). According to the Ministry of Health there is no separate regulatory category for CBG and CBD as dietary supplements.

Key legal implications for consumers: products with CBG and CBD <0.3% THC can be legally purchased, possessed, and used in Poland. However, manufacturers cannot declare medicinal properties (only registered drugs, e.g., Epidiolex, can), which is in line with the position WHO ECDD (2018).

The second issue, CBD flower as a "collectible item" is in a gray regulatory area, formally legal with <0.3% THC, but consumption through vaporization is sometimes questioned. Oils, capsules, and cosmetics have a clear status. Thirdly, CBD/CBG e-liquids are subject to tobacco law and excise duty.

Quote capsule: CBG and CBD are legal in Poland provided the THC content is below 0.3% (Act of July 29, 2005, on counteracting drug addiction, with the 2022 amendment). Manufacturers cannot declare medicinal properties; this is in line with the WHO ECDD position (2018). Only registered drugs (e.g., Epidiolex) can.

Safety and side effects of CBG vs CBD: what is worth knowing?

According to the report WHO ECDD (2018) CBD shows a "good safety profile" in humans, even at doses up to 1500 mg/day. The most common side effects (>10% of patients in Epidiolex studies) are: drowsiness, decreased appetite, diarrhea, fatigue, elevated liver aminotransferases (ALT/AST). For CBG, safety data mainly comes from animal studies.

Key drug interactions of CBD

• Clobazam, doubling the level of N-desmethylclobazam (CYP2C19), increased sedation
• Warfarin, increased INR, risk of bleeding (CYP2C9)
• Statins, increased their levels (CYP3A4), risk of myopathy
• SSRIs/SNRIs, possible enhancement of the serotonin effect
• Tramadol, risk of serotonin syndrome

Safety profile of CBG

CBG has a lower potential for interactions with CYP450 than CBD, but data is sparse. The main risks arise from α2AR agonism: lowering blood pressure, bradycardia, sedation. Patients taking antihypertensive medications (especially clonidine, brimonidine, beta-blockers) should exercise caution. Dry mouth is a common side effect of both cannabinoids.

Quote capsule: WHO ECDD (2018) assesses CBD as "well tolerated in humans even at doses of 1500 mg/day". The most common side effects are drowsiness, diarrhea, and fatigue. CBG has a lower potential for interactions with CYP450, but caution is required in patients on antihypertensive medications due to α2-adrenergic agonism.

When to use both cannabinoids together: 5 situations?

The combination of CBG and CBD is justified in cases with multiple pathophysiological mechanisms. Full-spectrum extracts naturally contain mixtures of cannabinoids (with a predominance of CBD and trace amounts of CBG, CBC, CBN, CBG), reflecting the idea of entourage. According to Russo (2011) such a composition works more broadly than an isolate.

1. IBS with an anxiety component, CBG for intestinal inflammation + CBD for anxiety and sleep
2. Fibromyalgia, CBD for chronic pain + CBG for the inflammatory component
3. Psoriasis, atopic dermatitis, CBD for itching and anxiety + CBG for inflammation and skin microbiome
4. Oncology as support, CBG for appetite + CBD for sleep and nausea (after consultation)
5. Migraine with photophobia, CBD for pain + CBG for any inflammatory component

In a survey of ~120 customers of the cannabis store u Bucha (February 2026), 38% of those using CBG combined it with CBD in a 1:1 ratio, 27% in a 1:2 ratio (more CBD), 18% used CBG alone, 17% other ratios.

Quote capsule: The combination of CBG and CBD makes sense in conditions with multiple mechanisms: IBS with anxiety, fibromyalgia, psoriasis, oncology as support, migraine. According to Russo (British Journal of Pharmacology, 2011), full-spectrum extracts work more broadly than isolates, and the most popular CBG:CBD ratio among Polish consumers is 1:1 (38%) or 1:2 (27%).

Frequently Asked Questions (FAQ)

1. CBG or CBD to start, what to choose?

To start, choose CBD; it has more clinical data, is cheaper, and has broader indications (anxiety, sleep, pain). Start with 10 mg twice daily of 5% oil, titrate every 5-7 days by 5-10 mg. Add CBG only after 4-6 weeks if the effect of CBD is incomplete or you have a dominant inflammatory component (IBS, dermatology).

2. Can I combine CBG and CBD in one dosage?

Yes, combining is safe and often more effective due to the entourage effect (Russo, 2011). The most popular ratios are 1:1 and 1:2 CBG:CBD. You can either use a combined product (e.g., oil with two cannabinoids) or dose two oils independently. Maintain a 30-minute break if you are taking other medications.

3. Is CBG better than CBD for inflammation?

In inflammatory bowel conditions (IBD, IBS), CBG has stronger preclinical data than CBD (Borrelli et al., 2013). In systemic inflammatory conditions (arthritis, dermatology), the difference is smaller, and the combination of CBG + CBD yields the best results. CBD has better-documented activity for inflammatory pain with a neuropathic component.

4. Why is CBG 2-3 times more expensive than CBD?

Because in typical hemp strains, CBG constitutes only ~1% of the dry weight of the inflorescence, while CBD is 8-20% (Calapai et al., 2022). To obtain one kilogram of CBG, several times more biomass must be processed, plus it requires harvesting in the early flowering phase (before CBGA converts to other cannabinoids). The selection of high CBG strains is gradually lowering the price.

5. Does CBG have psychoactive effects?

No. CBG, like CBD, is non-psychoactive and does not induce euphoria or intoxication. It is a weak partial agonist of CB1 receptors (Ki 380-2600 nM), too weak to produce a "high". However, it may affect mood through 5-HT1A antagonism and α2AR agonism, which in some individuals results in a "calm focus".

6. Are CBG and CBD legal in Poland in 2026?

Yes, both are legal provided they come from hemp with THC content below 0.3% (Act of July 29, 2005, amendment 2022). Manufacturers cannot declare medicinal properties. Flower in smoking/vaporization form is in a regulatory gray area, oils, capsules, and cosmetics have a clear legal status.

7. Will CBG and CBD affect a drug test?

Pure CBG and CBD isolates should not yield a positive result, as tests detect THC and its metabolites. Full-spectrum products contain trace amounts of THC (up to 0.3%) and with regular use of high doses (>50 mg/day) may yield a positive result. Employees required to undergo drug testing should choose isolate or broad-spectrum.

8. Can I use CBG/CBD during pregnancy?

No. There is insufficient safety data on cannabinoids in pregnant and breastfeeding women. According to ACOG (2017) cannabinoids can cross the placental barrier and are detected in breast milk. It is generally recommended to refrain from cannabinoids during pregnancy and lactation.

9. How long do CBG and CBD take to work?

Sublingual oil: effect after 15-45 minutes (bioavailability 13-19%), peak after 1-2 hours, duration of action 4-6 hours. Capsules: effect after 60-90 minutes (bioavailability 4-12%), duration 6-8 hours. Vaporization: effect in 5-10 minutes, but shorter (2-3 hours). Full therapeutic effect with regular use usually after 2-4 weeks (Millar et al., 2018).

10. What to check in the COA before purchasing a CBG/CBD product?

Five key items: (1) cannabinoid profile matching the label ±10%, (2) THC content below 0.3%, (3) no detectable pesticides, (4) heavy metals (Pb, Cd, Hg, As) within standards, (5) microbiology and mycotoxins without exceedances. According to FDA (2021), less than 30% of tested CBD products meet the declared content; COA is absolutely the basis of trust.

Summary: how to make a decision between CBG vs CBD?

The choice between CBG and CBD should not be binary. For most users, the optimal strategy "CBD as a base, CBG as a targeted supplement". CBD has better-documented efficacy in humans (Whiting et al., 2015), while CBG surpasses it in inflammatory bowel conditions, glaucoma, bacterial infections, and appetite support. Full entourage (full-spectrum) usually beats isolate (Russo, 2011).

Practical decision-making path: start with good, researched CBD 5-10% (e.g., SOOL CBD 5% or 10%), titrate for 4-6 weeks. If the effect is incomplete and you have a clear inflammatory or infectious component, add CBG (e.g., Cannova CBG 15% precisely dosed). Always check the COA, consult with a doctor for chronic medications, and remember that cannabinoids are a supplement, not a replacement for therapy.

how to choose CBD oil step by step – instructional pillar entourage effect – an article on cannabinoid synergy

Recommended CBG and CBD products from the store u Bucha

• SOOL CBD 5% (76 PLN), a classic start for those just getting to know CBD, 500 mg of CBD in 10 ml
• SOOL CBD 10% (99 PLN), optimal price/dose ratio, 1000 mg of CBD for pain and sleep
• Cannova CBG 15% (240 PLN), reference high CBG oil, 1500 mg of CBG for precise higher doses
• Mars Dry CBD 9% (59 PLN), an alternative for those preferring vaporization, CBD hemp flower